Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esmolol combined with HAT for sepsis and septic shock
ChiCTR1900027674Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Dec 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of esmolol, hydrocortisone, ascorbic acid and thiamine in sepsis and septic shock (3 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoints: Arterial blood gas analysis, Blood routine test and 6 more. Planned start Dec 2019; status: not yet recruiting.
02
Drugs
esmololhydrocortisoneascorbic acidthiamine
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on ChiCTR1900027674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027674.